期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Metabolite acetyl-L-carnitine participates in Bifidobacterium animalis F1-7 to ameliorate atherosclerotic inflammation by downregulating theTLR4/NF-κB pathway
1
作者 Xi Liang Zhe Zhang +7 位作者 Xiaoying Tian Qingyu Cui Haiyan Lu Maozhen Zhao Tongjie Liu Huaxi Yi pimin gong Lanwei Zhang 《Food Science and Human Wellness》 SCIE CSCD 2024年第2期813-822,共10页
This study aimed to explore the effect of Bifidobacterium animalis F1-7 on the improvement of atherosclerotic inflammation.Arteriosclerosis model ApoE^(-/-)mice were orally administered with B.animalis F1-7 for 12 wee... This study aimed to explore the effect of Bifidobacterium animalis F1-7 on the improvement of atherosclerotic inflammation.Arteriosclerosis model ApoE^(-/-)mice were orally administered with B.animalis F1-7 for 12 weeks.The probiotic intervention reduced the plaque areas in aorta and the accumulation of macrophages,and downregulated the expression of toll-like receptor 4(TLR4)/nuclear factorκB(NF-κB)pathway to reduce the levels of inflammatory factors.The widely-targeted metabolomics analysis showed that acetyl-L-carnitine(ALC)in the intestine of atherosclerotic mice was significantly increased after B.animalis F1-7 intervention.Correlation analysis proved that ALC was associated with atherosclerotic inflammatory response.By using oxidized low density lipoprotein induced macrophage foam cells,we further verified that ALC could reduce lipid accumulation and inflammatory response in foam cells by downregulating the TLR4/NF-κB pathway.Finally,our results revealed that B.animalis F1-7 upregulated the metabolite ALC to downregulate the inflammatory responses,leading to the reduction of plaque accumulation of atherosclerosis. 展开更多
关键词 Bifidobacterium animalis F1-7 Atherosclerosis INFLAMMATION METABONOMICS ACETYL-L-CARNITINE
下载PDF
More than a Few LAB Alleviate Common Allergies: Impact of Paraprobiotics in Comparison to Probiotical Live Cells
2
作者 Nditange Shigwedha Lanwei Zhang +7 位作者 Liubov Sichel Li Jia pimin gong Wenli Liu Shumei Wang Shuang Zhang Xue Han Wei Gao 《Journal of Biosciences and Medicines》 2014年第3期56-64,共9页
The evidence in this paper indicates that the alarming increase of common allergies can be reduced by the intake of particular “probiotics” or “paraprobiotics” along with food. This appears to build a consensus in... The evidence in this paper indicates that the alarming increase of common allergies can be reduced by the intake of particular “probiotics” or “paraprobiotics” along with food. This appears to build a consensus in the pharmaceutical and food communities about the role of probiotics in the prevention and treatments of common allergies. Food allergy is one of the common allergies, defined as an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Improving the digestion of foods and maintaining a healthy gastrointestinal (GI) tract is certainly critical to controlling food allergens. Therefore, the association between a leaky gut or an impaired intestinal permeability and food-allergenic reactions is explained. Gluten has been found to be somehow a justification for protein allergy, and should, therefore, be avoided by people with celiac disease. In several, in vitro models, surface layer (S- layer) proteins of selective paraprobiotics have shown potential in alleviating food allergies and intestinal disorders. Notably, lactobacilli paraprobiotics have proven to be the immediate immunomodulators against common allergies and other diseases, including viral (flu, hepatitis C), bacterial (bronchitis), asthma, chronic fatigue, fibromyalgia, gastrointestinal distress, and autism disorders in humans. 展开更多
关键词 Paraprobiotics Food ALLERGY S-LAYER Proteins Immunoglobulin E (IgE) Probiotical Cell Lysates LACTIC Acid Bacteria (LAB)
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部